| Jenna Christen Campbell, APN | |
|
1312 W Collin Raye Dr, De Queen, AR 71832-2135 | |
| (870) 584-7115 | |
| (870) 642-3388 |
| Full Name | Jenna Christen Campbell |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 12 Years |
| Location | 1312 W Collin Raye Dr, De Queen, Arkansas |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790039162 | NPI | - | NPPES |
| A003780 | Other | AR | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | A003780 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Arkansas Counseling And Guidance Center, Inc | 1355326174 | 26 |
News Archive
Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
The proportion of deaths attributable to diabetes in the U.S. is as high as 12 percent - three times higher than estimates based on death certificates suggest, according to a new analysis led by a Boston University School of Public Health researcher.
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
On March 23, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "TMJ: Stem Cell Biology and Engineering toward Clinical Translation" will provide a rare forum for multidisciplinary discussion of the biology, engineering and clinical translation of fundamental discoveries towards novel clinical therapy.
› Verified 1 days ago
| Entity Name | Western Arkansas Counseling & Guidance Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326040692 PECOS PAC ID: 1355326174 Enrollment ID: O20040623001595 |
News Archive
Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
The proportion of deaths attributable to diabetes in the U.S. is as high as 12 percent - three times higher than estimates based on death certificates suggest, according to a new analysis led by a Boston University School of Public Health researcher.
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
On March 23, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "TMJ: Stem Cell Biology and Engineering toward Clinical Translation" will provide a rare forum for multidisciplinary discussion of the biology, engineering and clinical translation of fundamental discoveries towards novel clinical therapy.
› Verified 1 days ago
| Entity Name | Southwest Arkansas Counseling And Mental Health Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598761553 PECOS PAC ID: 1456339852 Enrollment ID: O20040712001144 |
News Archive
Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
The proportion of deaths attributable to diabetes in the U.S. is as high as 12 percent - three times higher than estimates based on death certificates suggest, according to a new analysis led by a Boston University School of Public Health researcher.
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
On March 23, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "TMJ: Stem Cell Biology and Engineering toward Clinical Translation" will provide a rare forum for multidisciplinary discussion of the biology, engineering and clinical translation of fundamental discoveries towards novel clinical therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jenna Christen Campbell, APN 2904 Arkansas Blvd, Texarkana, AR 71854-2536 Ph: (870) 773-4655 | Jenna Christen Campbell, APN 1312 W Collin Raye Dr, De Queen, AR 71832-2135 Ph: (870) 584-7115 |
News Archive
Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
The proportion of deaths attributable to diabetes in the U.S. is as high as 12 percent - three times higher than estimates based on death certificates suggest, according to a new analysis led by a Boston University School of Public Health researcher.
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.
On March 23, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "TMJ: Stem Cell Biology and Engineering toward Clinical Translation" will provide a rare forum for multidisciplinary discussion of the biology, engineering and clinical translation of fundamental discoveries towards novel clinical therapy.
› Verified 1 days ago
Bonita Lois Martin, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 500 E Collin Raye Dr, De Queen, AR 71832 Phone: 870-584-1055 | |
John Robert Dean Bailey, APRN-CNP, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1021 W Collin Raye Dr, De Queen, AR 71832 Phone: 870-518-0018 Fax: 870-627-3532 | |
Samantha Kay Davis, MSN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1553 W Collin Raye Dr, De Queen, AR 71832 Phone: 870-584-3000 | |
Kara Lynn Osuna, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1553 W Collin Raye Dr, De Queen, AR 71832 Phone: 870-584-3000 Fax: 870-584-3003 | |
Meaghan Elana Harder, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1553 W Collin Raye Dr, De Queen, AR 71832 Phone: 870-584-3000 Fax: 870-584-3003 | |
Autumn Dawn Morales, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 503 E Collin Raye Dr, De Queen, AR 71832 Phone: 870-557-7362 | |
Mrs. Colleen Michelle Janes, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1553 W Collin Raye Dr, De Queen, AR 71832 Phone: 870-584-3000 Fax: 870-584-3003 |